Nivolumab-induced folliculitis: A case of immune-related cutaneous adverse reaction

ABSTRACT: Nivolumab, a human IgG4 PD-1 immune checkpoint inhibitor antibody, blocks PD-1 and can restore anticancer immune responses by impairing T-cell suppression via the PD-1 pathway. Nivolumab is generally well-tolerated, with fewer treatment-related adverse events (AEs) than other systemic therapies. Here we report a case of nivolumab-induced folliculitis involving the lower limbs in a 35-year-old male. The patient had multiple follicular-based pustules over the bilateral legs with surrounding erythema. The patient was treated with topical steroids, which resulted in complete resolution.